Neuronetics, Inc.
STIM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.04 | 0.12 | -0.38 | 0.22 |
| FCF Yield | -63.54% | -41.40% | -18.40% | -26.70% |
| EV / EBITDA | -3.32 | -3.77 | -4.83 | -2.20 |
| Quality | ||||
| ROIC | -30.20% | -31.52% | -35.96% | -21.84% |
| Gross Margin | 72.32% | 72.47% | 76.26% | 78.93% |
| Cash Conversion Ratio | 0.71 | 1.06 | 0.83 | 0.90 |
| Growth | ||||
| Revenue 3-Year CAGR | 4.72% | 8.86% | 9.81% | -4.07% |
| Free Cash Flow Growth | 5.65% | -1.17% | -12.10% | -4.18% |
| Safety | ||||
| Net Debt / EBITDA | -1.84 | -0.12 | 0.96 | 2.04 |
| Interest Coverage | -4.74 | -5.63 | -9.75 | -8.35 |
| Efficiency | ||||
| Inventory Turnover | 4.88 | 2.43 | 1.74 | 1.78 |
| Cash Conversion Cycle | -1.89 | 153.34 | 229.80 | 122.25 |